P L Olliaro

Summary

Affiliation: World Health Organization
Country: Switzerland

Publications

  1. ncbi Mode of action and mechanisms of resistance for antimalarial drugs
    P Olliaro
    World Health Organization, Communicable Diseases Cluster CDS, UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases TDR, CH 1211 27, Geneva, Switzerland
    Pharmacol Ther 89:207-19. 2001
  2. ncbi Plasmodium falciparum: an electronmicroscopy study of caveolae and trafficking between the parasite and the extracellular medium
    P Olliaro
    UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
    Int J Parasitol 27:1007-12. 1997
  3. ncbi Possible modes of action of the artemisinin-type compounds
    P L Olliaro
    UNDP World Bank WHO Special Programme on Research and Training in Tropical Diseases, CDS Cluster, 20, Avenue Appia, CH 1211, Geneva, Switzerland
    Trends Parasitol 17:122-6. 2001
  4. ncbi Controlling malaria: challenges and solutions
    P Olliaro
    UNDP World Bank World Health Organization Special Program for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
    Trop Med Int Health 6:922-7. 2001
  5. ncbi Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: A review
    P L Olliaro
    UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, CH 1211 Geneva 27, Switzerland
    J Postgrad Med 50:40-4. 2004
  6. ncbi What role can public health institutions play in drug development for the poor? A case study of artesunate
    M Gomes
    Special Programme for Research and Training in Tropical Diseases, TDR WHO, Geneva, Switzerland
    Med Trop (Mars) 58:97-100. 1998
  7. ncbi Pharmacokinetics of artesunate after single oral administration to rats
    P L Olliaro
    UNPD World Bank WHO Special Programme for Research and Training in Tropical Diseases TDR, CDS, World Health Organization, 20, avenue AppiaCH 1211 Geneva 27, Switzerland
    BMC Pharmacol 1:12. 2001
  8. ncbi The global portfolio of new antimalarial medicines under development
    P Olliaro
    UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
    Clin Pharmacol Ther 85:584-95. 2009
  9. ncbi Status of antimalarial drugs under development
    P L Olliaro
    Steering Committee on Drugs for Malaria, UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 73:565-71. 1995
  10. ncbi Phagocytosis of hemozoin (native and synthetic malaria pigment), and Plasmodium falciparum intraerythrocyte-stage parasites by human and mouse phagocytes
    P Olliaro
    UNDP WorldBank WHO Special Programme for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
    Ultrastruct Pathol 24:9-13. 2000

Detail Information

Publications11

  1. ncbi Mode of action and mechanisms of resistance for antimalarial drugs
    P Olliaro
    World Health Organization, Communicable Diseases Cluster CDS, UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases TDR, CH 1211 27, Geneva, Switzerland
    Pharmacol Ther 89:207-19. 2001
    ..The use of closely related compounds has promoted the spread of multidrug resistant parasites. This review intends to collate contemporary knowledge, and also to highlight conflicting views on unresolved issues...
  2. ncbi Plasmodium falciparum: an electronmicroscopy study of caveolae and trafficking between the parasite and the extracellular medium
    P Olliaro
    UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
    Int J Parasitol 27:1007-12. 1997
    ..They may constitute carrier vesicles containing parasite membrane transport molecules possibly involved in malaria pathogenesis and/or immunity...
  3. ncbi Possible modes of action of the artemisinin-type compounds
    P L Olliaro
    UNDP World Bank WHO Special Programme on Research and Training in Tropical Diseases, CDS Cluster, 20, Avenue Appia, CH 1211, Geneva, Switzerland
    Trends Parasitol 17:122-6. 2001
    ..However, uncertainties remain as to how they act on the parasite and cause toxicity. In this review, we summarize current ideas...
  4. ncbi Controlling malaria: challenges and solutions
    P Olliaro
    UNDP World Bank World Health Organization Special Program for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
    Trop Med Int Health 6:922-7. 2001
    ..The paper describes a multilateral, multidisciplinary research project on artemisinin-based combination therapy, which offers a new and potentially highly effective way to prevent or retard the development of drug resistance...
  5. ncbi Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: A review
    P L Olliaro
    UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, CH 1211 Geneva 27, Switzerland
    J Postgrad Med 50:40-4. 2004
    ..This review will summarise current antimalarial drug developments and outline recent clinical research that aims to bring artemisinin based combinations to those that need them most...
  6. ncbi What role can public health institutions play in drug development for the poor? A case study of artesunate
    M Gomes
    Special Programme for Research and Training in Tropical Diseases, TDR WHO, Geneva, Switzerland
    Med Trop (Mars) 58:97-100. 1998
    ..In essence, each and every player has rallied in the challenge to reduce the discrepancy between need and availability of a drug that can has the potential to reduce mortality form the disease...
  7. ncbi Pharmacokinetics of artesunate after single oral administration to rats
    P L Olliaro
    UNPD World Bank WHO Special Programme for Research and Training in Tropical Diseases TDR, CDS, World Health Organization, 20, avenue AppiaCH 1211 Geneva 27, Switzerland
    BMC Pharmacol 1:12. 2001
    ..In order to study the absorption phase of the kinetics of artesunate following oral administration in rats, samples were collected at baseline, and then 0.5, 2, 5, 10, 15, 30, 45, 60 and 120 minutes after a single dose of 150 mg...
  8. ncbi The global portfolio of new antimalarial medicines under development
    P Olliaro
    UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
    Clin Pharmacol Ther 85:584-95. 2009
    ..The portfolio is discussed in terms of the novelty of the new molecules and their potential health impact in terms of addressing the requirements for the control and eventual eradication of malaria...
  9. ncbi Status of antimalarial drugs under development
    P L Olliaro
    Steering Committee on Drugs for Malaria, UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 73:565-71. 1995
    ..Some of these drugs may become available in the next few years. It is therefore essential to find mechanisms to ensure that they are made available at an affordable price to the populations that really need them...
  10. ncbi Phagocytosis of hemozoin (native and synthetic malaria pigment), and Plasmodium falciparum intraerythrocyte-stage parasites by human and mouse phagocytes
    P Olliaro
    UNDP WorldBank WHO Special Programme for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
    Ultrastruct Pathol 24:9-13. 2000
    ..On the contrary, whole parasites appear to follow a classical endocytic pathway. This suggests that there may be differences between the ingestion of free particles and whole parasites in terms of modulation of phagocytes' functions...
  11. ncbi Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial
    M F Gomes
    UNICEF UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
    Lancet 373:557-66. 2009
    ..We investigated whether this intervention reduced mortality and permanent disability...